Warning: Undefined array key "network" in /hshare1/ZETTAI_path_WA_slash_usr_slash_proj_KARA/usr/proj/tcng/htdocs/tcng.php on line 565
Edge
PIK3CD → PIM1
Networks Including this Edge
| GSE11121_egf1520 - GSE11121 - SiGN-BN HC+Bootstrap | The humoral immune system has a key prognostic impact in node-negative breast cancer |
| GSE12093_egf1520 - GSE12093 - SiGN-BN HC+Bootstrap | The 76-gene Signature Defines High-Risk Patients that Benefit from Adjuvant Tamoxifen Therapy |
| GSE14208_egf1520 - GSE14208 - SiGN-BN HC+Bootstrap | Clinical response of metastatic gastric cancer patients to cisplatin and fluorouracil (CF) combination chemotherapy |
| GSE14210_egf1520 - GSE14210 - SiGN-BN HC+Bootstrap | Expression data from human endoscopic biopsy samples |
| GSE14814_egf1520 - GSE14814 - SiGN-BN HC+Bootstrap | Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer |
| GSE17705_egf1520 - GSE17705 - SiGN-BN HC+Bootstrap | Endocrine Sensitivity Index Validation Dataset |
| GSE19615_egf1520 - GSE19615 - SiGN-BN HC+Bootstrap | Integrated genomic and function characterization of the 8q22 gain |
| GSE20194_egf1520 - GSE20194 - SiGN-BN HC+Bootstrap | MAQC-II Project: human breast cancer (BR) data set |
| GSE20916_egf1520 - GSE20916 - SiGN-BN HC+Bootstrap | Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data |
| GSE21653_egf1520 - GSE21653 - SiGN-BN HC+Bootstrap | A gene expression signature identifies two prognostic subgroups of basal breast cancer |
| GSE22093_egf1520 - GSE22093 - SiGN-BN HC+Bootstrap | Expression data from breast cancer FNA biopsies from patients |
| GSE22597_egf1520 - GSE22597 - SiGN-BN HC+Bootstrap | Expression data from Fine Needle Aspiration (FNA) biopsies from breast cancer patients |
| GSE23988_egf1520 - GSE23988 - SiGN-BN HC+Bootstrap | Expression data from breast cancer FNA biopsies from patients (US samples) |
| GSE25055_egf1520 - GSE25055 - SiGN-BN HC+Bootstrap | Discovery cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE25065_egf1520 - GSE25065 - SiGN-BN HC+Bootstrap | Validation cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE25066_egf1520 - GSE25066 - SiGN-BN HC+Bootstrap | Genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE2603_egf1520 - GSE2603 - SiGN-BN HC+Bootstrap | Subpopulations of MDA-MB-231 and Primary Breast Cancers |
| GSE26639_egf1520 - GSE26639 - SiGN-BN HC+Bootstrap | Expression Data from 226 patients of the REMAGUS02 trial |
| GSE26906_egf1520 - GSE26906 - SiGN-BN HC+Bootstrap | APC colon stage II |
| GSE32269_egf1520 - GSE32269 - SiGN-BN HC+Bootstrap | Expression data for primary localized prostate cancer versus castration-resistant bone metastatic prostate cancer |
| GSE5460_egf1520 - GSE5460 - SiGN-BN HC+Bootstrap | Predicting Features of Breast Cancer with Gene Expression Patterns |
| GSE6481_egf1520 - GSE6481 - SiGN-BN HC+Bootstrap | Gene Expression Analysis of Soft Tissue Sarcomas: Characterization & Reclassification of Malignant Fibrous Histiocytoma |
| GSE7390_egf1520 - GSE7390 - SiGN-BN HC+Bootstrap | Strong Time Dependence of the 76-Gene Prognostic Signature |
| GSE9195_egf1520 - GSE9195 - SiGN-BN HC+Bootstrap | Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen |
